|
Post by bwills on Oct 22, 2016 17:51:21 GMT -5
Was the endo Ms. Kronen's endo or someone else. It sounds like it probably wasn't her personal endo. It would have been a lot better to have had her endo discuss why he chose to use it.
|
|
|
Post by sportsrancho on Oct 28, 2016 10:20:52 GMT -5
Laura said over 50 people have contacted her.
By that she means get Afrezza in front of the people!
|
|
|
Post by sportsrancho on Oct 28, 2016 10:44:47 GMT -5
|
|
|
Post by surplusvalue on Oct 28, 2016 10:48:27 GMT -5
MNKD management doesnt seem to understand this, does it?
|
|
|
Post by sportsrancho on Oct 28, 2016 10:57:19 GMT -5
MNKD management doesnt seem to understand this, does it? IMO they do not. We need a few good men like Mannmade to get the top Endo's on board. And the rest of the resources should go to getting Afrezza in front of the people! Laura is a great at marketing and being a spokesperson.
|
|
|
Post by surplusvalue on Oct 28, 2016 11:08:44 GMT -5
MNKD management doesnt seem to understand this, does it? IMO they do not. We need a few good men like Mannmade to get the top Endo's on board. And the rest of the resources should go to getting Afrezza in front of the people! Laura is a great at marketing and being a spokesperson. From what I can see they have spent most of their limited resources on the endo "education" and very little (so far) on DTC efforts. (JD walks may be good for the future but does little for the immediate issues).This is the same mistake Sanofi made (when they were actually doing anything). I agree that Laura would, and is readily available to be, a great spokesperson. She is bright, assertive, attractive , knowledgeable, and in control of her diabetes; all the things MNKD could want in a spokesperson and all the things from a marketing perspective that people would like to project themselves to be like. In short, very positive. MNKD could have used the magazine interview and spread to their advantage to use another medium as well at the same time.
|
|
|
Post by sportsrancho on Oct 28, 2016 11:09:01 GMT -5
|
|
|
Post by nadathing on Oct 28, 2016 11:18:16 GMT -5
There is a reason why there are so many commercials on TV for drugs. It drives sales. Thousands of PWD demanding Afrezza from their doctors would have worked, but MNKD didn't have the money for it or made a poor decision not to pursue it. As a result, there is no demand for Afrezza. It was obvious that TS had no value after no BP's stepped up to partner with MNKD on it. Now it is obvious Afrezza has no value. SNY was right. I can't imagine anyone wanting to buy MNKD at any price. Call me whatever you like, but I am depressed beyond words over a situation that now appears hopeless.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 28, 2016 11:27:13 GMT -5
Per Mike C at this years annual shareholders meeting, a decent TV campaign with an absolute minimum rate of spend is $20mm. Mannkind had neither the money or adequate insurance coverage for this - volume of prior auth paperwork in concentrated time period would likely have PO'd docs big time. Those ads in sports programs were a waste as was the tents set up at JDRF - if this were big pharma with deep pockets, these types of things are awareness initiatives with marginal impact on patient but more of a positioning / let your competition know you are there type of thing. Big pharma can afford to piss away some of their money, spend it or lose it and the marketing folks like some of the visible stuff to help make it appear like they are worthy of their paychecks. In Mannkind's position, it should have been all about sales - shoe leather and elbow grease with a laser focus on the top endo's in the country. If even a few hundred of the big endo practices were supporting Afrezza, TRx count would be several times where it is today. Maybe something big and positive happens in the next few weeks but I doubt it.
|
|
|
Post by surplusvalue on Oct 28, 2016 11:36:43 GMT -5
Per Mike C at this years annual shareholders meeting, a decent TV campaign with an absolute minimum rate of spend is $20mm. Mannkind had neither the money or adequate insurance coverage for this - volume of prior auth paperwork in concentrated time period would likely have PO'd docs big time. Those ads in sports programs were a waste as was the tents set up at JDRF - if this were big pharma with deep pockets, these types of things are awareness initiatives with marginal impact on patient but more of a positioning / let your competition know you are there type of thing. Big pharma can afford to piss away some of their money, spend it or lose it and the marketing folks like some of the visible stuff to help make it appear like they are worthy of their paychecks. In Mannkind's position, it should have been all about sales - shoe leather and elbow grease with a laser focus on the top endo's in the country. If even a few hundred of the big endo practices were supporting Afrezza, TRx count would be several times where it is today. Maybe something big and positive happens in the next few weeks but I doubt it. The TV campaign could have been targeted for "the top health shows" not necessarily TV ads in general. I suggested this route even for CEO appearance some time ago; even better for a spokesperson like Laura. Throwing out a 20M figure is just an excuse for lazy marketing. As for endos MNKD hasnt even been able to properly manage their endo list (who is on it and who isnt) from a number of reports, let alone the top endos. I dont think its quite over as I have posted elsewhere but I do share your doubts about the future with management's silence on the most pressing issues.
|
|
|
Post by sportsrancho on Oct 28, 2016 11:57:12 GMT -5
Per Mike C at this years annual shareholders meeting, a decent TV campaign with an absolute minimum rate of spend is $20mm. Mannkind had neither the money or adequate insurance coverage for this - volume of prior auth paperwork in concentrated time period would likely have PO'd docs big time. Those ads in sports programs were a waste as was the tents set up at JDRF - if this were big pharma with deep pockets, these types of things are awareness initiatives with marginal impact on patient but more of a positioning / let your competition know you are there type of thing. Big pharma can afford to piss away some of their money, spend it or lose it and the marketing folks like some of the visible stuff to help make it appear like they are worthy of their paychecks. In Mannkind's position, it should have been all about sales - shoe leather and elbow grease with a laser focus on the top endo's in the country. If even a few hundred of the big endo practices were supporting Afrezza, TRx count would be several times where it is today. Maybe something big and positive happens in the next few weeks but I doubt it. The TV campaign could have been targeted for "the top health shows" not necessarily TV ads in general. I suggested this route even for CEO appearance some time ago; even better for a spokesperson like Laura. Throwing out a 20M figure is just an excuse for lazy marketing. As for endos MNKD hasnt even been able to properly manage their endo list (who is on it and who isnt) from a number of reports, let alone the top endos. I dont think its quite over as I have posted elsewhere but I do share your doubts about the future with management's silence on the most pressing issues. Exactly, Laura is talking about being a spokesperson for Afrezza on news shows all over the US. Not so much about TV commercials. I thought the same thing that we were making the same mistake SNY did:-(. I do have faith Mike knows what he doing. Although I do not have faith the reps do. And I'm also looking forward to an explanation:-)
|
|
|
Post by zuegirdor on Oct 28, 2016 12:00:31 GMT -5
Per Mike C at this years annual shareholders meeting, a decent TV campaign with an absolute minimum rate of spend is $20mm. Mannkind had neither the money or adequate insurance coverage for this - volume of prior auth paperwork in concentrated time period would likely have PO'd docs big time. Those ads in sports programs were a waste as was the tents set up at JDRF - if this were big pharma with deep pockets, these types of things are awareness initiatives with marginal impact on patient but more of a positioning / let your competition know you are there type of thing. Big pharma can afford to piss away some of their money, spend it or lose it and the marketing folks like some of the visible stuff to help make it appear like they are worthy of their paychecks. In Mannkind's position, it should have been all about sales - shoe leather and elbow grease with a laser focus on the top endo's in the country. If even a few hundred of the big endo practices were supporting Afrezza, TRx count would be several times where it is today. Maybe something big and positive happens in the next few weeks but I doubt it. The TV campaign could have been targeted for "the top health shows" not necessarily TV ads in general. I suggested this route even for CEO appearance some time ago; even better for a spokesperson like Laura. Throwing out a 20M figure is just an excuse for lazy marketing. As for endos MNKD hasnt even been able to properly manage their endo list (who is on it and who isnt) from a number of reports, let alone the top endos. I dont think its quite over as I have posted elsewhere but I do share your doubts about the future with management's silence on the most pressing issues. IMHO someone needs to contact the pulmonary specialists at Mannkind (and on FDA panel?) that were used in the trial analysis. As I recall the lung docs advising the trial did not have lung issue concerns. The hyperinsulinemia, growth factor and fibroid concerns have to be dispelled or de-emphaiszed consistent with what we know about 1)Normoglycemic physiology 2)Rapid acting analogue PK/PD 3)RAA IGF receptor affinity 4) RAA depot in fat and lipohypertrophy 5)Afrezza's fast in fast out of the lungs action 6) T2 hyperinsulinemia . The endos are confused about this. Yes uncertainties remain. These should be considered separately from Afrezza's superior PK/PD. And only time will tell us all. Meanwhile, there is not a doctor on the ward that can tell a diabetic that their day to day risk of earlt death outweighs real or imagined risk of using Afrezza. Yes this pulomonoligist has a hard sell. He needs to get on the Dr K Oz Oprah circuit and explain but he also needs to get the attention of the endos, who, in my expereince really don't have the depth to answer the lung question for themselves. Who else is going to do it? No one wants to admit ignorance. Better the status quo. Leanne mentioned someone from another board who recently lost a friend to a hypo death. This patient was denied Afrezza just days before. how many times does this have to happen unitl endos get it?
|
|
|
Post by liane on Oct 28, 2016 14:14:15 GMT -5
The moderators have had a busy day today. At times we have to take things down first and ask questions later. surplusvalue - the one post you referred to has been restored. I ask that you have a bit more respect for other posters if you think you have been misunderstood. On days like today, a little courtesy goes a long way.
|
|
|
Post by surplusvalue on Oct 28, 2016 14:23:29 GMT -5
The moderators have had a busy day today. At times we have to take things down first and ask questions later. surplusvalue - the one post you referred to has been restored. I ask that you have a bit more respect for other posters if you think you have been misunderstood. On days like today, a little courtesy goes a long way. Liane, Thanks for the reply and appreciate your moderate moderation by restoring the original post. I read your response about respect after just finishing a reponse to nylefty so I wasnt perhaps so kindly to him but respect is due where it belongs and I cant abide false accusations and clear distortions of my posts.Those other posts you removed were given in good faith and not meant to be personal or disrespectful but rather to the point and direct and I even stated this in the last post that was removed. Obviously, I cannot control whether other posters "read" my posts or how they take my posts meant to correct them. However, courtesy goes both ways; people reading other posts should have the courtesy and take the time to read carefully.
|
|